Neurofilament light as a prognostic marker in multiple sclerosis

Area of Science:

• Neuroscience
• Clinical Neurology
• Biomarker Research

Background:

• Relapsing-remitting multiple sclerosis (RRMS) prognosis is variable.
• A reliable laboratory prognostic marker for RRMS is currently lacking.
• Identifying early indicators of disease severity is crucial for patient management.

Purpose of the Study:

• To investigate the association between cerebrospinal fluid (CSF) neurofilament light (NfL) levels in early multiple sclerosis (MS).
• To determine if CSF NfL levels predict long-term disease severity and progression.
• To evaluate NfL as a potential prognostic marker in early RRMS.

Main Methods:

• CSF NfL levels were measured in 99 early MS patients at diagnostic lumbar puncture.
• Clinical data were collected at a median of 14 years post-onset from 95 patients.
• Statistical analyses included correlation, multivariate logistic regression, and Kaplan-Meier survival analysis.

Main Results:

• Significant correlations were found between CSF NfL levels and the Multiple Sclerosis Severity Score (MSSS).
• Elevated CSF NfL levels (>386 ng/L) were associated with a fivefold increased risk of severe MS.
• Higher NfL levels correlated with increased likelihood of conversion to secondary-progressive MS.

Conclusions:

• Elevated CSF NfL levels at diagnosis are linked to unfavorable long-term prognosis in MS.
• CSF NfL shows potential as a prognostic biomarker for disease severity and progression in early RRMS.
• This finding aids in predicting long-term outcomes for individuals with early MS.